GleamWall
中文EN

DSGN Design Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1807120 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-9.8%
TTM EPS YoY-0.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-36.9%
ROA-34.6%
ROIC (approx.)-35.0%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets6.7%
Debt / equity0.00x
Current ratio16.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-6.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q12026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$0$0—
R&D expense$16.93M$16.39M$14.38M$13.43M$14.59M$15.74M$15.38M$12.16M
SG&A expense$5.30M$5.79M$5.33M$4.74M$4.72M$5.83M$5.04M$4.54M
Operating income-$22.23M-$22.18M-$19.71M-$18.17M-$19.31M-$21.57M-$20.42M-$16.69M
Net income-$20.29M-$20.16M-$17.64M-$16.00M-$17.00M-$19.08M-$17.71M-$13.65M
EBITDA-$22.09M-$22.03M-$19.55M-$18.01M-$19.16M-$21.42M-$20.26M-$16.55M
EPS (basic)-0.32-0.32-0.29—-0.30-0.34-0.31—
EPS (diluted)-0.32-0.32-0.29—-0.30-0.34-0.31—
Weighted avg. shares (diluted)63.04M62.51M61.43M—56.95M56.86M56.76M—
Balance sheet
Cash & equivalents$15.25M$12.91M$12.77M$16.86M$15.09M$19.70M$13.67M$22.56M
Short-term investments$193.36M$194.49M$210.05M$202.99M$190.88M$196.57M$216.01M$222.91M
Current assets$213.96M$212.01M$227.05M$223.78M$209.03M$219.79M$233.64M$248.04M
PP&E, net$573,000$694,000$824,000$981,000$1.10M$1.26M$1.38M$1.41M
Total assets$216.81M$215.13M$230.44M$226.20M$211.77M$222.89M$237.47M$252.09M
Current liabilities$12.75M$11.24M$10.19M$13.05M$11.17M$8.75M$8.24M$8.46M
Total liabilities$14.61M$13.27M$12.39M$13.70M$12.05M$9.85M$9.56M$10.00M
Shareholders' equity$202.20M$201.86M$218.05M$212.50M$199.72M$213.04M$227.92M$242.10M
Shares outstanding63.79M62.58M62.44M60.40M56.96M56.95M56.77M56.75M
Cash flow statement
Operating cash flow-$15.38M-$15.52M-$16.43M-$11.97M-$11.16M-$14.44M-$16.79M-$9.86M
Capital expenditure$15,000$21,000$0$34,000$0$87,000$72,000$0
Free cash flow-$15.39M-$15.54M-$16.43M-$12.00M-$11.16M-$14.53M-$16.86M-$9.86M
Investing cash flow$189,000$15.06M-$7.59M-$11.58M$6.51M$20.12M$7.87M$1.83M
Financing cash flow$17.53M$605,000$19.93M$25.32M$37,000$361,000$23,000$263,000
Depreciation & amortization$136,000$151,000$157,000$156,000$155,000$152,000$159,000$149,000
Stock-based compensation$4.05M$3.87M$3.92M$3.44M$3.59M$3.98M$3.54M$3.47M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.